Cargando…

Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B

BACKGROUND/AIMS: Decay of hepatitis B surface antigen (HBsAg) titers has previously been shown to be predictive of a virologic response (VR), especially during peginterferon-alpha therapy. However, the role of HBsAg levels in predicting a VR to nucleos(t)ide analog therapy has not yet been establish...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Joon Chang, Min, Bo Young, Kim, Jin-Wook, Kim, Jong Yeop, Kim, Yeo Myeong, Shin, Cheol Min, Lee, Sang Hyub, Hwang, Jin-Hyeok, Jeong, Sook-Hyang, Kim, Nayoung, Lee, Dong Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304662/ https://www.ncbi.nlm.nih.gov/pubmed/22310791 http://dx.doi.org/10.3350/kjhep.2011.17.4.268

Ejemplares similares

Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse
por: Tseng, Tzu-Ning, et al.
Publicado: (2022)

Comparison of the Clinical Features of Hepatitis A between HBsAg-Positive and HBsAg-Negative Patients
por: Kim, Kwang Min, et al.
Publicado: (2011)

Comparison of Serum HBsAg Quantitation by Four Immunoassays, and Relationships of HBsAg Level with HBV Replication and HBV Genotypes
por: Tuaillon, Edouard, et al.
Publicado: (2012)

Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination
por: Galati, Giovanni, et al.
Publicado: (2014)

Dilemma of HBsAg seroconversion in chronic hepatitis B infection: Dilemma of HBsAg in chronic HBV
por: Alavian, Seyed Moayed, et al.
Publicado: (2011)

Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
por: Gupta, Ekta, et al.
Publicado: (2023)

The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance
por: Jiang, Shaowen, et al.
Publicado: (2023)

IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir
por: Zhao, Kai, et al.
Publicado: (2017)

Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients
por: Liu, Xin, et al.
Publicado: (2023)

Clinical and Virological Characteristics of Chronic Hepatitis B Patients with Coexistence of HBsAg and Anti-HBs
por: Liu, Yong, et al.
Publicado: (2016)

Dynamic changes of HBV markers and HBV DNA load in infants born to HBsAg(+) mothers: can positivity of HBsAg or HBV DNA at birth be an indicator for HBV infection of infants?
por: Chen, Tianyan, et al.
Publicado: (2013)

A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro
por: Salpini, Romina, et al.
Publicado: (2020)

Accuracy Validation of the Elecsys HBsAg II Quant Assay and Its Utility in Resolving Equivocal Qualitative HBsAg Results
por: Lee, Jaehyeon, et al.
Publicado: (2023)

Occult HBV infection in HCC and cirrhotic tissue of HBsAg-negative patients: a virological and clinical study
por: Coppola, Nicola, et al.
Publicado: (2016)

Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection
por: Salpini, Romina, et al.
Publicado: (2020)

Reduced HBV cccDNA and HBsAg in HBV-associated hepatocellular carcinoma tissues
por: Tantiwetrueangdet, Anchalee, et al.
Publicado: (2018)

HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure
por: Moini, Maryam, et al.
Publicado: (2022)

The role of HBsAg levels in the current management of chronic HBV infection
por: Höner zu Siederdissen, Christoph, et al.
Publicado: (2014)

Prediction Model of HBsAg Seroclearance in Patients with Chronic HBV Infection
por: Cao, Jing, et al.
Publicado: (2020)

Correlation Between HBsAg Quantitation and HBV DNA in HBeAg-Negative HBV/D Patients
por: Teriaky, Anouar, et al.
Publicado: (2013)

Paradoxical HBsAg and anti-HBs coexistence among Chronic HBV Infections: Causes and Consequences
por: Jiang, Xinyi, et al.
Publicado: (2021)

Pre-transplant donor HBV DNA+ and male recipient are independent risk factors for treatment failure in HBsAg+ donors to HBsAg- kidney transplant recipients
por: Wang, Xian-ding, et al.
Publicado: (2021)

Clinical Outcomes of Delayed Clearance of Serum HBsAg in Patients with Chronic HBV Infection
por: Nam, Soon Woo, et al.
Publicado: (2007)

Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs
por: Huang, Jing, et al.
Publicado: (2017)

Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies
por: Piermatteo, Lorenzo, et al.
Publicado: (2023)

Development of a Rapid Automated Fluorescent Lateral Flow Immunoassay to Detect Hepatitis B Surface Antigen (HBsAg), Antibody to HBsAg, and Antibody to Hepatitis C
por: Ryu, Ji Hyeong, et al.
Publicado: (2018)

Correlation between HBsAg quantitative assay results and HBV DNA levels in chronic HBV
por: Ganji, Azita, et al.
Publicado: (2011)

Long-term outcomes of HBsAg/anti-HBs double-positive versus HBsAg single-positive patients with chronic hepatitis B
por: Kwak, Min-Sun, et al.
Publicado: (2019)

Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients
por: Cerva, Carlotta, et al.
Publicado: (2022)

HBV Genotyping in HBsAg-Positive Blood Donors from Southwestern Iran
por: Kohshour, Mojtaba Oraki, et al.
Publicado: (2010)

Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients
por: Kim, Jin Hyang, et al.
Publicado: (2020)

Analytical Performance of the Sysmex HISCL HBsAg Assay and Comparison with the Roche Elecsys HBsAg II Quant Assay in the Quantification of Hepatitis B Surface Antigen
por: Park, Joonhong, et al.
Publicado: (2021)

A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine
por: Choi, Yu-Min, et al.
Publicado: (2023)

Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes
por: Scheiblauer, H, et al.
Publicado: (2010)

HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT
por: Gu, Ha Ra, et al.
Publicado: (2015)

Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Comparative analysis of the safety and efficacy of HBsAg-1018 versus HBsAg-Eng: a meta-analysis
por: ZHANG, LIN L., et al.
Publicado: (2020)

B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
por: Kruse, Robert L., et al.
Publicado: (2017)

Free episomal and integrated HBV DNA in HBsAg-negative patients with intrahepatic cholangiocarcinoma
por: Pollicino, Teresa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mbqaeae2jm0q048io2jh4hpklg